Global Blood TherapeuticsRecent Data Breaches and Security Report

https://gbt.com  ᛫  Biotech & Pharmaceuticals
Last updated October 26, 2018

Company Details

Company Overview

GBT is a clinical-stage biopharmaceutical company determined to discover, develop and deliver innovative treatments that provide hope to underserved patient communities. GBT is developing its late-stage product candidate, voxelotor (previously called GBT440), for the treatment of sickle cell disease.

Valuation

Employees

CEO

Ted W. Love, M.D.

Location

Recent Data Breaches

Stay informed about the most recent data breaches affecting companies like Global Blood Therapeutics

subscribe to data breach notifications

Security Rating

Sorry, this security report couldn't be loaded at this time. Please try again later.

UpGuard's Cyber Security Ratings range from 0 to 950. The higher the score, the more effective a company is in implementing good security practices.

Passed Checks

Passed{{ passedCheck.passTitle }}

Failed Checks

Warning{{ failedCheck.failTitle }}

View a free security report for Global Blood Therapeutics

Get full security report ›

See UpGuard In Action

Book a call with one of our specialists and we'll arrange a time for a demo.